coronavirus
posit
strand
rna
virus
infect
anim
particularli
bat
minor
number
also
caus
human
diseas
human
coronavirus
broadli
divid
type
coronaviru
merscov
famili
four
major
surfac
protein
help
viru
enter
cell
viz
envelop
protein
e
spike
protein
nucleocapsid
n
protein
membran
protein
spike
protein
transmembran
glycoprotein
made
subunit
protein
crucial
viru
entri
bind
fusion
host
cell
subunit
receptor
bind
domain
rbd
bind
receptor
host
subunit
contain
heptad
repeat
form
main
membran
fusion
unit
e
protein
requir
assembl
intracellular
transport
bud
viru
protein
role
viral
morphogenesi
assembl
n
protein
e
protein
interact
form
complet
viru
particl
addit
structur
protein
merscov
two
larg
polyprotein
call
protein
broken
proteas
form
variou
nonstructur
essenti
protein
enzym
recent
studi
reveal
viral
structur
nonstructur
protein
exploit
novel
target
therapeut
purpos
infect
caus
merscov
averag
incub
time
day
day
rang
host
time
period
show
symptom
infect
clinic
symptom
diseas
rang
mild
symptom
upper
respiratori
infect
like
cough
fever
myalgia
sever
form
pneumon
well
respiratori
failur
patient
may
also
suffer
abdomin
pain
appetit
loss
nausea
diarrhea
vomit
gastrointestin
symptom
less
commonli
occur
symptom
includ
hemoptysi
diarrhea
without
hint
fever
studi
advoc
chronic
ill
chronic
heart
diseas
kidney
diseas
diabet
hypertens
increas
risk
merscov
infect
sever
though
proof
requir
merscov
alter
antigen
present
host
immun
respons
modul
apoptot
pathway
mitogenactiv
protein
kinas
pathway
discoveri
merscov
sarscov
consid
pathogen
coronaviru
howev
higher
pathogen
merscov
appar
higher
number
death
caus
viru
similar
viru
sar
merscov
infect
replic
human
airway
epitheli
cell
suppress
product
interferon
howev
unlik
sarscov
mer
viru
exhibit
wider
tissu
tropism
merscov
also
induc
proinflammatori
cytokin
lack
product
innat
antivir
cytokin
compar
sarscov
suggest
merscov
induc
delay
proinflammatori
respons
attenu
innat
immun
suggest
merscov
lethal
compar
sarscov
primarili
mer
viru
interact
host
receptor
spike
protein
enter
respiratori
tract
receptor
present
epitheli
surfac
variou
human
organ
lung
kidney
liver
bone
marrow
thymu
intestin
system
distribut
facilit
dissemin
viru
human
bodi
express
respiratori
tract
mainli
type
type
ii
pneumocyt
endotheli
cell
noncili
bronchial
epitheli
cell
form
hematopoiet
cell
abund
receptor
greater
epitheli
cell
line
lower
airway
alveoli
lesser
epitheli
surfac
upper
conduct
airway
nasal
caviti
recent
find
suggest
prior
exist
pulmonari
ailment
might
increas
chanc
individu
contract
mer
chronic
pulmonari
diseas
result
enhanc
express
cov
seriou
virul
factor
facilit
biolog
action
merscov
studi
advanc
understand
pathogen
merscov
facilit
develop
better
therapeut
host
gene
express
infect
cell
suppress
merscov
also
promot
viru
assembl
bud
vitro
lead
effici
viru
replic
suggest
also
critic
merscov
replic
promot
product
viru
particl
host
sever
merscov
infect
rel
patient
comorbid
condit
chronic
lung
diseas
renal
failur
diabet
other
compromis
immun
system
understand
merscov
pathogenesi
limit
due
nonavail
patient
autopsi
patholog
sampl
patient
understand
diseas
pathogenesi
base
entir
vitro
studi
studi
conduct
anim
model
human
lung
cell
line
account
singl
autopsi
vitro
studi
reveal
merscov
easili
replic
sever
cultur
human
cell
well
differenti
nondifferenti
human
epitheli
cell
antigen
merscov
found
macrophag
alveoli
infect
human
lung
explant
ciliat
noncili
bronchial
epitheli
cell
endotheli
cell
pneumocyt
find
sync
find
made
singl
autopsi
merscov
antigen
detect
pneumocyt
endotheli
cell
epitheli
cell
airway
macrophag
macrophag
import
phagocyt
cell
innat
immun
system
help
remov
pathogen
substanc
bodi
present
antigen
cell
cytokin
well
chemokin
produc
macrophag
help
destroy
pathogen
adjust
immun
system
maintain
tissu
homoeostasi
howev
mer
virusinfect
macrophag
contribut
consider
develop
diseas
symptom
infect
merscov
human
epitheli
cell
induc
releas
proinflammatori
chemokin
cytokin
monocytederiv
macrophag
believ
chemokinescytokin
caus
inflammatori
chang
tissu
injuri
infiltr
immun
cell
lower
respiratori
tract
patient
suffer
mer
clinic
manifest
pneumonia
progress
natur
larg
number
macrophag
neutrophil
found
fluid
present
lung
studi
conduct
rhesu
macaqu
shown
lung
tissu
infiltr
macrophag
neutrophil
merscov
infect
though
respiratori
symptom
milder
compar
human
mani
scientist
believ
sequestr
immun
cell
contribut
develop
lymphopenia
seen
patient
mer
progress
sever
pneumonia
respiratori
dysfunct
mer
patient
also
attribut
cytokinechemokin
induct
zhou
et
al
found
merscov
effici
replic
insid
macrophag
henc
overcom
host
immun
system
thu
phagocyt
act
like
reservoir
mean
transport
virus
help
replic
dissemin
hiv
viru
infect
epitheli
cell
mer
viru
induc
slow
signific
ifn
type
ii
respons
macrophag
releas
proinflammatori
chemokin
cytokin
upon
merscov
infect
similarli
merscov
infect
blood
monocytederiv
macrophag
dendrit
cell
lead
releas
chemokin
cytokin
exampl
rant
infect
activ
cell
induc
apoptosi
via
differ
pathway
may
also
explain
occurr
lymphopenia
present
avail
knowledg
difficult
describ
exact
pathogenesi
merscov
seem
viral
replic
macrophag
result
extrem
cytotox
trigger
induct
proinflammatori
chemic
may
lead
mersassoci
complic
small
number
epitheli
pneumocyt
lymphoid
aggreg
inflammatori
cell
submucos
gland
posit
mer
spike
protein
nonhuman
primat
nhp
wherea
mer
spike
antigen
posit
epitheli
layer
submucos
bronchial
gland
lung
nhp
cell
balt
dual
immunohistochemistri
method
appli
use
monoclon
antibodi
mer
spike
protein
stain
show
mer
found
posit
cell
neg
nhp
two
nhp
common
marmoset
rhesu
macaqu
model
establish
merscov
infect
three
differ
research
group
clinic
symptom
includ
respiratori
diseas
mild
natur
could
diagnos
radio
imag
comput
tomographi
respiratori
diseas
sever
natur
show
fatal
clinic
symptom
requir
euthanasia
exposur
infecti
clone
strain
rhesu
monkey
report
caus
respiratori
diseas
wherein
viru
antigen
detect
respiratori
diseas
case
found
transient
mild
natur
resolv
day
infect
pulmonari
diseas
also
found
mild
upon
merscov
infect
nhp
earlier
studi
found
ocular
intratrach
intranas
exposur
mersemc
isol
caus
lethal
diseas
howev
argu
lethal
due
manipul
marmoset
higher
sensit
macaqu
speci
case
mild
moder
symptom
even
higher
viral
titer
also
report
studi
small
anim
hamster
mice
found
resist
merscov
infect
develop
model
sever
respiratori
diseas
challeng
identif
highli
pathogen
merscov
suggest
coronavirus
present
incess
longterm
hazard
human
develop
effect
therapeut
prophylact
agent
contain
infect
urgent
need
yet
current
antivir
treatment
merscov
avail
merscov
known
interact
host
cell
surfac
receptor
spike
protein
subsequ
lead
entri
host
cell
knowledg
regard
exact
mechan
follow
thereaft
still
limit
requir
research
due
lack
definit
treatment
support
therapi
remain
solut
present
develop
consist
previou
experi
coronaviru
diseas
like
sarscov
studi
vitro
vivo
model
tremend
effort
made
direct
variou
antivir
relat
therapi
identifi
use
human
monoclon
antibodi
convalesc
plasma
therapeut
peptid
shown
efficaci
repurpos
current
avail
drug
also
tri
extend
efficaci
merscov
potenti
option
discuss
detail
concept
use
clinic
avail
drug
treat
new
diseas
known
repurpos
method
new
target
profil
creat
exist
drug
screen
larg
molecular
databas
owe
advanc
comput
approach
develop
effect
antivir
agent
repurpos
becom
faster
use
highthroughput
screen
research
abl
screen
larg
librari
drug
novel
target
evalu
antivir
activ
vitro
repurpos
drug
shown
potent
antivir
activ
merscov
exampl
ribavirin
nitazoxanid
hexachloropen
studi
repurpos
drug
use
combin
two
exist
drug
wild
et
al
combin
alisporivir
ribavirin
enhanc
antivir
activ
mer
sarscov
anoth
studi
merscov
infect
marmoset
hybrid
ritonavirlopinavir
posit
effect
convalesc
plasma
therapi
util
plasma
whole
blood
peopl
infect
viral
diseas
recov
therapi
use
outbreak
particular
medicin
vaccin
avail
treatment
use
convalesc
plasma
indic
effici
therapeut
strategi
diseas
like
merscov
studi
carri
confirm
feasibl
safeti
treat
mer
howev
data
insuffici
drawback
therapi
often
largescal
screen
requir
obtain
suffici
amount
antibodi
potenti
donor
monoclon
antibodi
commonli
use
diagnosi
variou
diseas
therapeut
base
monoclon
antibodi
use
success
therapi
variou
diseas
potenti
approach
acknowledg
coronavirus
sar
outbreak
deadli
coronaviru
attack
human
previou
knowledg
help
greatli
improv
respons
risk
merscov
initi
studi
suggest
merscov
rbd
domain
glycoprotein
repres
suitabl
target
develop
neutral
monoclon
antibodi
henc
idea
develop
neutral
mous
mab
strategi
prevent
entri
merscov
host
cell
led
du
et
al
mab
made
vaccin
mice
fc
recombin
merscov
fuse
consequ
effect
murin
mab
develop
target
merscov
rbd
success
neutral
merscov
infect
vero
cell
studi
indic
potenti
human
mab
effici
cur
agent
infect
caus
merscov
around
april
three
independ
studi
first
report
develop
complet
human
merscov
neutral
mab
human
mab
specif
target
merscov
rbd
glycoprotein
efficaci
human
mab
merscov
infect
first
exhibit
qiu
et
al
abl
complet
treat
merscov
infect
lethal
natur
singl
dose
human
mab
transgen
mous
develop
human
monoclon
antibodi
emerg
viral
diseas
requir
signific
product
cost
pose
major
drawback
overcom
obstacl
reduc
cost
extrem
power
neutral
mab
given
smaller
dose
without
compromis
efficaci
need
one
strategi
achiev
could
design
human
mab
except
bind
attract
target
potenti
target
rbd
recent
interest
gener
develop
peptid
therapeut
potenti
drug
target
differ
pathogen
current
peptid
therapeut
line
clinic
evalu
present
peptid
research
compon
pharmaceut
research
compar
chemic
drug
peptid
drug
show
high
specif
toward
target
well
littl
side
effect
drug
toler
mani
peptid
therapeut
shown
posit
result
viral
infect
instanc
peptid
rift
valley
fever
viru
peptid
deriv
scorpion
venom
antimicrobi
peptid
cite
potenti
novel
antivir
therapeut
coronavirus
antimicrobi
peptid
produc
host
immun
system
upon
initi
exposur
pathogen
gene
encod
posit
charg
peptid
select
toxic
target
select
due
posit
charg
attack
neg
charg
membran
bilay
microb
antimicrobi
peptid
block
receptor
present
host
cell
surfac
turn
inhibit
differ
step
viral
fusion
replic
caus
virolysi
activ
host
adapt
immun
respons
sinc
emerg
merscov
research
greatli
enhanc
knowledg
pathogenesi
caus
contemporari
coronaviru
sarscov
effort
toward
develop
vaccin
deadli
viru
also
continu
increas
lead
emerg
promis
intervent
two
virus
word
sar
mer
common
challeng
develop
efficaci
vaccin
evid
report
age
popul
vulner
merscov
lesson
learnt
preclin
studi
sarscov
suggest
vaccin
fail
protect
age
anim
effect
young
one
similarli
clinic
set
risk
mortal
even
higher
individu
chronic
condit
immunocompromis
state
effect
vaccin
thu
offer
univers
protect
includ
vulner
popul
need
evalu
promis
vaccin
comorbid
chronic
condit
immunocompromis
rodent
model
sinc
viru
comfort
replic
macrophag
risk
vaccinederiv
immunopatholog
negat
must
consid
use
heterolog
challeng
model
balanc
must
struck
protect
excess
immun
activ
evalu
success
vaccin
candid
vaccin
develop
merscov
mostli
influenc
sarscov
howev
aid
develop
better
vaccin
need
enhanc
knowledg
patholog
merscov
outlin
critic
differ
sar
merscov
mab
offer
window
opportun
candid
shown
potenc
vitro
test
howev
care
need
taken
human
mab
minim
antimous
antibodi
respons
epitop
identifi
mous
neutral
mab
neutral
human
merscov
mab
target
rbd
report
higher
potenc
therapi
direct
protein
region
merscov
could
recogn
critic
residu
bind
howev
chang
critic
residu
may
render
mab
ineffect
lead
develop
escap
mutant
strain
viru
discuss
promis
peptid
also
develop
merscov
antivir
activ
stabil
solubl
peptid
improv
similar
peptid
develop
hiv
lead
develop
optim
next
gener
peptid
better
inhibitori
action
direct
merscov
altern
novel
approach
peptid
inhibitor
combin
mab
eg
rbd
specif
combin
evalu
synergist
effect
diverg
resist
strain
studi
also
need
explor
novel
deliveri
technolog
optim
vaccin
immun
suitabl
combin
adjuv
summari
encourag
result
area
develop
merscov
vaccin
preclin
set
howev
challeng
relat
efficaci
safeti
drug
deliveri
need
consider
proceed
clinic
trial
focus
research
direct
help
reduc
diseas
burden
caus
merscov
prevent
outbreak
especi
among
age
immunocompromis
popul
